Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda’s Tanigaki to Helm Nihon Pharm upon Full Acquisition
March 16, 2021
- AstraZeneca, Daiichi Sankyo to Wind Up Nexium Copromotion
March 16, 2021
- Takeda Appoints Milano Furuta as New Japan Chief
March 16, 2021
- Relumina Non-Inferior to Leuprorelin in Japan PIII Study for Endometriosis: ASKA
March 16, 2021
- Face-to-Face Promotions Down 16% in January as Pharma Switches to Online Meetings: Intage
March 16, 2021
- Kyowa Kirin Files G-Lasta for Label Expansion
March 15, 2021
- Takeda Seeks Japan Approval for HAE Med Lanadelumab
March 15, 2021
- Daiichi Sankyo Kicks Off AstraZeneca Vaccine Manufacturing in Japan
March 15, 2021
- Takeda Aims for 1 Trillion Yen Sales in Emerging Markets by FY2030
March 15, 2021
- Actemra-Remdesivir COVID-19 Combo Trial Fails, Chugai to Gauge Overall Data for Submission
March 12, 2021
- Sosei to Get US$2.5 Million Milestone Payment from Formosa
March 12, 2021
- Me Pharma Eyes Production of 1 Billion Tablets in FY2021, Sales Buoyed by Low Prices
March 12, 2021
- 5 Lysosomal Disease Drugs Now Available for Home Care: Sanofi
March 12, 2021
- Astellas Seeks Japan Nod for Padcev
March 12, 2021
- Keytruda Filed for TMB-H Solid Tumors in Japan: MSD
March 12, 2021
- Takeda, ANA to Test Drone Drug Delivery to Remote Islands in Nagasaki
March 12, 2021
- Kobayashi Kako to Invite Outsider to Take Over Top Post: Biz Improvement Plan
March 11, 2021
- Nichi-Iko to Stop Supply of 4 APIs/8 Products as Stocks Run Out
March 11, 2021
- JMA Affiliate Data Operator Poised to Provide RWD from NHO Hospitals to Drug Makers
March 11, 2021
- Takeda to Buy Out T-Cell Engager Specialist Maverick for US$525 Million
March 11, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…